Key result
Integrilin during PTCA and stenting is linked to 0% severe complications.
Why the study?
Is eptifibatide combined with aspirin, clopidogrel, and heparin safe and feasible in Chinese patients undergoing PTCA and stent implantation?
Observational (n=21)
Is eptifibatide combined with aspirin, clopidogrel, and heparin safe and feasible in Chinese patients undergoing PTCA and stent implantation?
The use of eptifibatide with dual antiplatelet therapy and heparin in Chinese patients undergoing PTCA and stenting appears safe, allowing for early sheath removal without increasing bleeding or thrombosis risk.
Answers are grounded in this paper and cite their sources.
May support eptifibatide safety in Chinese PTCA patients; leaves open confirmation in randomized trials.
Objective: to report the application of GPIIb/IIIa antagonist (Integrilin) in peri-percutaneous transluminal catheter angioplasty and stent implantation in Chinese. Method: Twenty-one patients who underwent percutaneous transluminal catheter angioplasty (PTCA) and stent implantation were included. After arterial puncture, integrilin was injected at dose of 180μg/kg, and then maintained at 2/μg/kg·min for 18 hours. Asprine, plavix(clopidogrel) and heparin were used at the same time. ACT, PT, KPTT and blood routine were routinely monitored. Results: All sheaths were drawn out 2 to 4 hours after the procedure., There was no severe complication such as hematoma, acute and subacute thrombosis in coronary artery, or thrombocytopenia. ACT returned to less than 150 seconds in 2 hours in 15 patients; in 4 hours in 6 patients. There was no significant difference between the pre- and post-procedure value of PT and platelet count. KPTT was significantly higher than pre-procedure value at 2 hours after the procedure. No recurrence of angina pectoris was observed in the first nine patients within one year follow-up, and no restenosis occurred in stents in the five patients who had coronary angiography one year later. Conclusion: Application of GPIIb/IIIa receptor antagonist (Integrilin) in peri-percutaneous transluminal catheter angioplasty and stent implantation in combination with aspirin and plavix could significantly reduce the dosage and duration of heparin with benefit of shortening the indwelling time of sheaths, but did not increase risk of bleeding or lead to thrombosis in stent.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2002) conducted an observational in Coronary artery disease requiring PTCA and stent implantation (n=21). GPIIb/IIIa antagonist (Integrilin) was evaluated on Severe complications (hematoma, acute and subacute thrombosis, thrombocytopenia). Application of Integrilin during PTCA and stent implantation in 21 patients resulted in 0% severe complications such as hematoma, acute thrombosis, or thrombocytopenia.
Synapse has enriched 10 related papers. Consider them for comparative context: